ARCT Arcturus Therapeutics
- 27.260
- +0.470+1.75%
- 26.740
- -0.520-1.91%
Arcturus Therapeutics News
Arcturus Therapeutics Is Maintained at Buy by Canaccord Genuity
Arcturus Therapeutics Is Maintained at Buy by Canaccord Genuity
Canadian Investment Banking Group: Maintaining the Arcturus Therapeutics (ARCT.US) rating, adjusted from buy to buy rating, and adjusted the target price from $87.00 to $86.00.
Canadian Investment Banking Group: Maintaining the Arcturus Therapeutics (ARCT.US) rating, adjusted from buy to buy rating, and adjusted the target price from $87.00 to $86.00.
Canaccord Genuity Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $86
Canaccord Genuity analyst Whitney Ijem maintains Arcturus Therapeutics with a Buy and lowers the price target from $87 to $86.
Arcturus Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 218.58% Canaccord Genuity $87 → $86 Maintains Buy 03/20/2024 122.26% HC Wainwright & Co. → $60
Buy Rating Affirmed for Arcturus Therapeutics Amidst Strong Financial Outlook and Promising Clinical Advancements
Earnings Call Summary | Arcturus Therapeutics(ARCT.US) Q1 2024 Earnings Conference
The following is a summary of the Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2024 Earnings Call Transcript:Financial Performance:Arcturus reported Q1 2024 revenues of $38 million, an increase from
Piper Sandler Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
Tesla CEO Elon Musk does not seem to agree with Republicans at least on one thing. On Wednesday, the billionaire, true to his credentials as a tech pioneer, unequivocally backed the mRNA technology, w
Arcturus Therapeutics Holdings Inc (ARCT) (Q1 2024) Earnings Call Transcript Highlights: ...
Arcturus Therapeutics | 10-Q: Quarterly report
Arcturus Therapeutics: JP Morgan Engaged to Monetize Investment in ARCALIS JV in Japan >ARCT
Arcturus Therapeutics: JP Morgan Engaged to Monetize Investment in ARCALIS JV in Japan >ARCT
Arcturus Therapeutics: Cash Runway Remains Strong for at Least 3 Years Into 1Q of FY27
Arcturus Therapeutics: Cash Runway Remains Strong for at Least 3 Years Into 1Q of FY27
Arcturus Therapeutics: Commercial Manufacture of Kostaive on Track for Delivery of Initial 4 M Doses in 3Q
Arcturus Therapeutics: Commercial Manufacture of Kostaive on Track for Delivery of Initial 4 M Doses in 3Q
Earnings Flash (ARCT) ARCTURUS THERAPEUTICS HOLDINGS Reports Q1 Revenue $38M, Vs. Street Est of $17.7M
04:03 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (ARCT) ARCTURUS THERAPEUTICS HOLDINGS Reports Q1 Revenue $38M, vs. Street Est of $17.7M
Arcturus Therapeutics Q1 EPS $(1.00) Beats $(1.19) Estimate, Sales $38.01M Beat $17.54M Estimate
Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(1.00) per share which beat the analyst consensus estimate of $(1.19) by 15.97 percent. This is a 153.48 percent decrease over earning
Arcturus Therapeutics 1Q Loss/Shr $1.00 >ARCT
Arcturus Therapeutics 1Q Loss/Shr $1.00 >ARCT
Arcturus Therapeutics 1Q Rev $38M >ARCT
Arcturus Therapeutics 1Q Rev $38M >ARCT
Arcturus Therapeutics 1Q Loss $26.8M >ARCT
Arcturus Therapeutics 1Q Loss $26.8M >ARCT
Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Investors Will Be Pleased With Their Impressive 284% Return Over the Last Five Years
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and
Analysis
Price Target
No Data
